Xyrem Settlement Gets Green Light

Law360 (July 13, 2007, 12:00 AM EDT) -- A federal judge on Friday approved Jazz Pharmaceuticals Inc.'s $20 million settlement with the federal government over an investigation into the promotion of Xyrem, a narcolepsy treatment containing oft-abused GHB, by Orphan Medical Inc., now a subsidiary of Jazz.

GHB, the popular name for gamma-hydroxybutyrate, is a powerful and almost immediate central nervous system depressant that is often illegally used for recreation. The Health and Human Services Department has classified it as a date rape drug.

Jazz' settlement figure, approved by Judge Eric Vitaliano of the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.